Analyses of Patient-Reported Outcomes with Mirvetuximab Soravtansine Versus Standard Chemotherapy in the Randomized Phase III FORWARD I Study in Ovarian Cancer

    September 2022 in “ Annals of Oncology ”
    K.N. Moore, A.M. Oza, N. Colombo … I.B. Vergote
    Studysummary This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on annalsofoncology.org →
    Discuss this study in the Community →